J. Aelion

发表

SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

C. Edwards, A. Wells, R. Stevens, 2014 .

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

R. Collins, C. Gordon, D. Isenberg, 2016, Arthritis & rheumatology.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

C. Edwards, F. Blanco, C. Birbara, 2016, Annals of the rheumatic diseases.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

R. Moots, P. Emery, D. Mevorach, 2017, The Lancet.

Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis.

L. Carbone, G. Somes, J. Seyer, 1999, Arthritis and rheumatism.

Eosinophilic pleural effusion: a review of 36 cases.

M. Lahav, A. Wysenbeek, J. Aelion, 1985, Respiration; international review of thoracic diseases.

Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study

E. Peeva, I. Bhattacharya, M. Greenwald, 2016, The Journal of Rheumatology.

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

P. Peloso, M. Genovese, M. Weinblatt, 2018, Rheumatology.

Characterization of unique human TCR V beta specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein.

E. Sokurenko, J. Takahara, M. Kotb, 1994, Journal of immunology.

Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis.

J. Travers, M. Kotb, P. Schlievert, 1995, The Journal of clinical investigation.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

A. Gottlieb, E. Martı́n-Mola, A. Deodhar, 2018, The Lancet.

Myopathy in sarcoidosis: clinical and pathologic study of four cases and review of the literature.

R. Pinals, J. Aelion, S. M. Wolfe, 1987, Seminars in arthritis and rheumatism.

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

P. Sfikakis, T. Takeuchi, H. Richards, 2018, Scandinavian journal of rheumatology.

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

A. Soliman, K. Papp, A. Östör, 2021, Annals of the Rheumatic Diseases.

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

M. Genovese, P. Durez, Sang-Heon Lee, 2014, The Journal of Rheumatology.

Treatment of calcinosis with diltiazem.

G. Wood, G. Palmieri, J. Aelion, 1995, Arthritis and rheumatism.

Evidence for preferential T cell receptor V beta gene usage and T cell clonal expansion in the synovium of BB rats with early-onset collagen-induced arthritis.

R. Endres, A. Kang, M. Cremer, 1998, Cellular immunology.

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

M. Genovese, A. Deodhar, T. Takeuchi, 2017, Rheumatology and Therapy.

Preservation of the specificity of superantigen to T cell receptor V beta elements in the absence of MHC class II molecules.

M. Kotb, A. Geller, T. Tanaka, 1993, Cellular immunology.

T cell receptor V gene usage by human T cells stimulated with the superantigen streptococcal M protein

G. Majumdar, M. Kotb, M. Tomai, 1991, The Journal of experimental medicine.

The porphyrogenic effects of calcium channel blocking drugs.

N. Schoenfeld, Y. Beigel, A. Atsmon, 1985, Clinical science.

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

J. Walsh, P. Nash, J. Gómez-Reino, 2018, Annals of the rheumatic diseases.

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

A. Deodhar, H. Marzo-Ortega, J. Sieper, 2016, Annals of the rheumatic diseases.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Patrick Durez, M. Genovese, V. Mazurov, 2012, Annals of the rheumatic diseases.

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

C. Edwards, A. Wells, A. Kivitz, 2018, Rheumatology.

Angioimmunoblastic lymphadenopathy and squamous cell carcinoma of lung.

Y. Lurie, C. Mor, J. Aelion, 1984, The American journal of the medical sciences.

THU0195 INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM

I. McInnes, E. Choy, J. Cush, 2020, Annals of the Rheumatic Diseases.

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

P. Peloso, M. Genovese, M. Weinblatt, 2018, Arthritis & rheumatology.

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study

A. Soliman, K. Papp, A. Östör, 2022, Rheumatology.

Concomitant rheumatoid arthritis and Marfan's syndrome.

S. Kaplan, J. Aelion, S. Wolfe, 1987, Arthritis and rheumatism.

Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients.

C. Edwards, A. Wells, A. Kivitz, 2021, Rheumatology.

Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial

F. Buttgereit, B. Rojkovich, H. Kupper, 2022, Arthritis & rheumatology.

Arthritis associated with ventriculoatrial shunt.

R. Pinals, J. Aelion, 1986, The Journal of rheumatology.

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

A. Wells, A. Kivitz, A. Kivitz, 2015 .